1Dienstag JL,Perrillo RR,Schiff ER,et al.A PPreliminary trial of Lamivudine for chronic hepatitis B infection[J].N Engl J Med,1995,333:1675.
2Schiff E,Cianciara J,Karayaicin,S,et al,The international lamivudineinvestigator group,Durable HbeAg and HbsAg seroconversion afterlamivudine forchronic hepatiti s B(abstr)[J].J Hepatol,2000,32:99.
3Goodman Z,Dhinon AP,WuPC,et al.Lamivudine treatment reducesprogression to cirrhosis in patients with chronic hepatitis B[J].J Hepatol,1999,30(S):59.
4Liaw y- F,Leung NWY,Chang TT,et al.Effects of eotended Lami-vudine therapy in Asian patients with chronie hepatitis B[J],Gastroenterology,2000,119(7):172.
5Leung NWY,Lai Ci,Chang TT,et al.Three year Lamivudine therapy in chronic HBV[J].J Hepatol,1999,30(S1):59
6Chang TT,Lai Ci,Ljan YF,et al.Incremental increases in HbeAg seroconversion and continued Alt normalization in Asian chronic HBV patients treated with Lamivudine for four years[J].Antiviral therapy,2000,5:44.
7Liaw YF, Chien RN,yeh CT,et al,Acute exacerbaion and hepatitis B viru sclearance after emergence of YMDD motify mutation during Lamivudine therapy[J].Hepatollgy,1999,30(2):567
8Allen MI,Deslaurier SM,Tipples GA,et al.Identification and cheracterizati on of mutations in Hepatitis B virus resistant to Lamivudine [J]. Hepatology,1998,27(6):1670.
9Heathcote EJ,Jeffers L,Wright T,et al.Loss of serum HBV DNA and HbeAg II andseroconvrsion following short-term(12weeks)adefovir dipivoxil therapy in chronic hepatitis B:two placebo- controlled phase II studies(abstr)[J].Hepatology,1998,28:317.
10Perrillo D,Schiff E,Yoshida E,et al.Adefvir dipivoxil for the treatment of Lamivudine- resistant hepatitis B mutants[J].Hepatology,2000,32(7):129.
